<DOC>
	<DOCNO>NCT00909168</DOCNO>
	<brief_summary>This prospective , open , non-randomized , non-controlled , phase II , clinical trial treatment newly diagnose AML patient , young 66 year . Trial base : - INDUCTION : FLAI + Gemtuzumab-Ozogamicin ( FLAI-GO ) . - CONSOLIDATION : Intermediate dose AraC + IDA ( IDAC+IDA ) +/- one course high dose AraC ( HDAC ) - INTENSIFICATION : Allo-BMT , ASCT - MAINTENANCE : AraC ) Primary endpoint : - Feasibility , Efficacy ( CR+PR rate ) Toxicity FLAI + Gemtuzumab-Ozogamicin . - RFS , DFS OS . b ) Secondary endpoint : - Evaluation Minimal Residual Disease WT1 ( biologic marker ) expression monitoring . - Evaluation prognostic clinical relevance biological feature onset . - Feasibility outcome consolidation BMT .</brief_summary>
	<brief_title>Induction , Consolidation Intensification Therapy Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Age 1865 year . WHO PS grade 02 ( Appendix B ) Karnofsky &gt; 70 . AML accord new WHO criterion , i.e. , % BM blast ≥ 20 % . NB . % assessed BM aspiration BM biopsy All FAB subtypes except M3 . CD33 positivity ( &gt; 20 % ) . It mandatory perform immunotyping BM blast particular determination CD33 positivity , use inclusion factor . Previously untreated ( except ≤ 14 day Hydroxyurea ) primary secondary AML ( include AML MDS ) . Adequate renal liver function , i.e. , creatinine &lt; 2 mg/dl bilirubin , ALT/AST ≤ 3 time upper limit normal . Written inform consent Blast crisis chronic myeloid leukemia . AML supervene myeloproliferative disease . AML de novo secondary previously pretreated . Concomitant malignant disease . Active central nervous system ( CNS ) leukemia . Active uncontrolled infection [ NB severe systemic infection exclude ] . Concomitant severe cardiovascular disease , i.e. , arrhythmia require chronic treatment , congestive heart failure symptomatic ischemic heart disease . Cardiac ejection fraction 50 % less . Severe pulmonary dysfunction ( CTC grade 34 ) . Severe concomitant neurological psychiatric disease . History alcohol abuse . HIV positivity . Pregnancy . Man woman agree adequate contraceptive precaution study period last 24 month stop therapy . Any psychological , familiar , sociological geographical condition potentially hamper compliance study protocol followup schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Induction chemotherapy</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Gemtuzumab Ozogamicin</keyword>
</DOC>